Full
Outline
From the perspective of the Chinese healthcare system, to evaluate the cost-effectiveness of enfortumab vedotin and pembrolizumab in the treatment of advanced urothelial carcinoma.
A dynamic Markov model was constructed based on data from the EV-302 trial, and cost-utility analysis (CUA) was used for economic evaluation. Deterministic (one-way) sensitivity analysis and probabilistic sensitivity analysis (PSA) were conducted on main parameters to verify the robustness of the base-case analysis results.
The analysis showed that for every additional quality-adjusted life year (QALY) in the enfortumab vedotin plus pembrolizumab group compared to the standard chemotherapy group, an additional cost of 2 358 823.11 yuan was required. The results of the deterministic sensitivity analysis showed that the most influential factors on incremental cost-effectiveness ratio (ICER) were the utility value of the progression-free state and the cost of enfortumab vedotin. The probabilistic sensitivity analysis results indicated that the combination of enfortumab vedotin and pembrolizumab was not cost-effective at a willingness-to-pay threshold equivalent to three times China's 2024 per capita GDP.
The combination of enfortumab vedotin and pembrolizumab does not represent a cost-effectiveness strategy compared with the standard chemotherapy group in the treatment of advanced urothelial carcinoma.
50
8
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
